Magtein’s UK authorisation opens frontiers for formulations

In a significant move for the British nutraceutical and functional food sectors, the magnesium compound Magtein (Magnesium L-threonate) has officially been authorised for use in the United Kingdom.

The authorisation marks a major milestone for its developer, Magceutics, and its global distribution partners, providing UK manufacturers with access to what is widely regarded as the only form of magnesium capable of effectively crossing the blood-brain barrier.

While magnesium is a staple in the supplement industry, traditional forms (such as citrate or oxide) often suffer from poor absorption in the brain. Magtein was developed by a team of MIT scientists to solve this specific physiological hurdle.

By significantly increasing magnesium levels in the brain, the compound has been clinically shown to support:

• Synaptic density: promoting the formation of new neural pathways.
• Cognitive function: improving memory, focus, and mental clarity.
• Stress management: supporting a healthy response to anxiety and improving sleep quality.

For food and drink manufacturers, the UK authorisation of Magtein arrives at a time of surging demand for brain health and nootropic products. As consumers move beyond simple energy boosts toward mental performance and longevity, Magtein offers a high-value, scientifically backed ingredient for premium formulations.

The compound’s stability and neutral taste profile make it a versatile addition to a variety of formats:

• Functional beverages: nootropic shots, “relaxation” drinks, and enhanced waters.
• Encapsulated supplements: high-potency cognitive health stacks.
• Gummies and chews: targeting the growing lifestyle supplement market.

The authorisation follows a rigorous review of safety and efficacy data, aligning the UK with other major markets like the United States, where Magtein has already established itself as a leading ingredient in the cognitive health category.

Rory Lipsky, Sr VP marketing, ThreoTech, LLC, said: “In the UK, as elsewhere, consumers are increasingly seeking out effective solutions for stress, sleep and cognitive wellbeing. Magnesium can be highly effective, but most forms struggle to deliver meaningful benefits because they don’t cross the blood-brain barrier to a sufficient degree. Magtein’s unique structure has a dramatic impact on brain bioavailability, and we’re delighted that its proven benefits can now be made available to consumers in one of the world’s most important magnesium markets.”

For manufacturers looking to differentiate their portfolios in the crowded VMS vitamins, minerals, and supplements) aisle, the inclusion of Magtein allows for more specific, high-tier health claims related to brain health and cognitive performance.

Magtein is now available to UK-based manufacturers through authorised ingredient distributors.